Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25699734 | 0.84 | CYP2D6 (0.34) | ACECYP2D6PTGS1PTGS2OPRK1 | |
| SCHEMBL28088919 | 0.82 | PTGS1 (0.40) | ACECYP2D6PTGS1PTGS2OPRK1 | |
| SCHEMBL765417 | 0.75 | — | — | |
| SCHEMBL2690883 | 0.75 | — | — | |
| SCHEMBL17427855 | 0.75 | — | — | |
| SCHEMBL13104108 | 0.72 | CYP2D6 (0.44) | ACECYP2D6PTGS1PTGS2OPRK1 | |
| SCHEMBL10453942 | 0.72 | CYP2D6 (0.44) | ACECYP2D6PTGS1PTGS2OPRK1 | |
| Methylamine SCHEMBL27257345 | 0.72 | CA1 (0.38) | TLR4CYP2D6PTGS1PTGS2OPRK1 | |
| SCHEMBL6913491 | 0.69 | CA1 (0.50) | TLR4CYP2D6KMT2A | |
| SCHEMBL919145 | 0.69 | CA1 (0.50) | TLR4CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339604-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | GENENTECH, INC. (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339604-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK2, JAK1, JAK3 | ACE 2658/4885TLR4 1049/4885CYP2D6 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.